Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:53:39.955Z.
Calculation as of: 2026-10-06T19:53:39.955Z.
Quote observation: 2026-10-06T19:50:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2fc0b38e6dc372860fd9bea61ccff40ee6de978c8f50a2bbdf53c6942eb71849
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Quince Therapeutics, Inc.
Market Cap
$7.59M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.59M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.74M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.52M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.86M | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.53M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.26M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
